StockMarketWire.com - Liquid biopsy Angle revealed Thursday the results of a recent study demonstrated a workflow for the recovery and culturing of circulating tumor cells growing outside of a patient using the firm's Parsortix system.

'This is the first time that an optimised workflow has been presented to culture cells growing outside the patient,' the firm said.

The parasortix system is a non-invasive method to provide a series of culture cells growing outside the patient, enabling patients to 'receive the right drug at the right time,' as some drugs become ineffective as the mutational profile of a patient's tumor evolves over time.

'Widely adopted, this approach has the potential to transform the way we treat cancer patients,' the firm said. 'The ability to recover, culture and interrogate cancer cells expands our possibility to advance precision medicine in breast cancer patients.'

At 8:54am: [LON:AGL] Angle PLC share price was +3.5p at 49.5p



Story provided by StockMarketWire.com